Evaluation of Anti-Tumor Antibodies for Cancer Treatment
Author Information
Author(s): Casey J L, Pedley R B, King D J, Green A J, Yarranton G T, Begent R H J
Primary Institution: Cancer Research Campaign Targeting and Imaging Group, Department of Oncology, Royal Free and University College Medical School
Hypothesis
Can cross-linked divalent and trivalent versions of the anti-carcinoembryonic antigen monoclonal antibody A5B7 be more effective alternatives in radioimmunotherapy for colorectal carcinoma?
Conclusion
The study suggests that 131I-DFM may be the best combination of antibody and radionuclide for radioimmunotherapy, offering lower toxicity to normal tissues.
Supporting Evidence
- Radiation doses were significantly higher in all tissues when antibodies were labelled with 90Y.
- The cumulative dose of 90Y-TFM to the kidney was three times lower than the divalent forms.
- TFM clears faster from the blood than IgG, producing higher tumour to blood ratios.
- For a similar level of toxicity and half the administered activity, 90Y-IgG produced a greater therapeutic response.
- Dosimetry analysis revealed that the tumour to normal tissue ratios were greater for all 131I-labelled antibodies.
Takeaway
Scientists tested different types of cancer-fighting antibodies to see which one works best with radiation treatment, and found that one specific combination is safer and more effective.
Methodology
The study involved comparative biodistribution studies using a human colorectal tumor mouse model to evaluate the effectiveness and safety of different antibody-radionuclide combinations.
Limitations
Further experiments at higher doses are required to determine the advantages of higher initial dose rates.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website